MILFORD, Mass., March 14, 2012 /PRNewswire/ -- PLC Systems Inc. (OTC: PLCSF), a company focused on innovative medical device technologies, today announced that it had received approval from the Israeli Ministry of Health to market its innovative RenalGuard System™ in that country. The company also announced it has signed a distribution agreement with A.M.I. Technologies, Ltd. Under the terms of the agreement, A.M.I. will be the exclusive distributor of PLC's RenalGuard® in Israel, expanding RenalGuard's distribution to the Middle East. As part of the agreement, A.M.I. has agreed to purchase an initial stocking order of RenalGuard consoles and single use sets.
PLC also announced that Dr. Eugenia Nikolsky, Director, Cardiovascular Research Unit, Rambam Medical Center, Haifa, Israel, has successfully completed the first patient case in Israel using RenalGuard for the prevention of Contrast-Induced Nephropathy (CIN).
Dr. Nikolsky, a noted expert on CIN, commented, "RenalGuard offers us a potential method to reduce the incidence of CIN, a major issue when performing interventional procedures requiring contrast agents with high-risk patients. I am very pleased to have the opportunity to utilize RenalGuard Therapy®, especially after seeing the positive results presented in both the REMEDIAL II and MYTHOS trials, and look forward to continued use of the system."
"Today's news enables PLC to expand the use of RenalGuard into the Middle East," said Mark R. Tauscher, President and Chief Executive Officer of PLC Systems. "A.M.I. is an established, successful distributor and will help in our efforts to increase worldwide adoption of RenalGuard. Many Israeli cardiologists, such as Dr. Nikolsky, are considered thought leaders in interventional cardiology worldwide. Our success in receiving approval to market RenalGuard in Israel should help us continue to drive adoption of RenalGuard worldwide."